A Mucormycosis Case in a Cirrhotic Patient Successfully Treated with Posaconazole and Review of Published Literature

Mycopathologia

Volumn 174, Issue 5-6, 2012, Pages 499-504

  Lin, Shang Yi ^a   Lu, Po Liang ^a,b   Tsai, Kun Bow ^c   Lin, Chun Yu ^a,b   Lin, Wei Ru ^a   Chen, Tun Chieh ^a,b   Chang, Ya Ting ^a   Huang, Chung Hao ^a   Chen, Chi Yu ^a   Lai, Chung Chih ^a   Chen, Yen Hsu ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Liver cirrhosis; Mucormycosis; Posaconazole

Indexed keywords

EID: 84869179814     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-012-9561-8     Document Type: Article

References (19)

1. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005; 41: 634-53.
2. Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005; 18: 556-69.
3. Abbas Z, Jafri W, Rasool S, Abid S, Hameed I. Mucormycosis in patients with complicated cirrhosis. Singapore Med J. 2007; 48: 69-73.
4. Pellicelli AM, D'Ambrosio C, Villani R, Cerasari G, Ialongo P, Cortese A, et al. Liver cirrhosis and rhino-orbital mucormycosis, a possible but rare association: description of a clinical case and literature review. Braz J Infect Dis. 2009; 13: 314-6.
5. Pillsbury HC, Fischer ND. Rhinocerebral mucormycosis. Arch Otolaryngol. 1977; 103: 600-4.
6. McNulty JS. Rhinocerebral mucormycosis: predisposing factors. Laryngoscope. 1982; 92: 1140-3.
7. Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002; 35: 140-8.
8. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005; 41: 422-33.
9. Cheruvattath R, Balan V. Infections in patients with end-stage liver disease. J Clin Gastroenterol. 2007; 41: 403-11.
10. Christin L, Wysong DR, Meshulam T, Hastey R, Simons ER, Diamond RD. Human platelets damage Aspergillus fumigatus hyphae and may supplement killing by neutrophils. Infect Immun. 1998; 66: 1181-9.
11. Sturtevant JE, Latge JP. Interactions between conidia of Aspergillus fumigatus and human complement component C3. Infect Immun. 1992; 60: 1913-8.
12. Ruping M, Heinz WJ, Kindo AJ, Rickerts V, Lass-Florl C, Beisel C, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother. 2010; 65: 296-302.
13. van Burik JAH, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006; 42: E61-5.
14. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis. 2005; 5: 775-85.
15. Moton A, Krishna G, Ma L, O'Mara E, Prasad P, McLeod J, et al. Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment. Curr Med Res Opin. 2010; 26: 1-7.
16. Torres-Narbona M, Guinea J, Martinez-Alarcon J, Munoz P, Pelaez T, Bouza E. Workload and clinical significance of the isolation of zygomycetes in a tertiary general hospital. Med Mycol. 2008; 46: 225-30.
17. Branscomb R. An overview of mucormycosis. Lab Med. 2002; 33: 453-5.
18. Ataseven H, Yuksel I, Gultuna S, Koklu S, Uysal S, Basar O, et al. Fatal rhinocerebral mucormycosis under the shade of hepatic encephalopathy. Ann Hepatol. 2010; 9: 462-4.
19. Georgopoulou S, Kounougeri E, Katsenos C, Rizos M, Michalopoulos A. Rhinocerebral mucormycosis in a patient with cirrhosis and chronic renal failure. Hepatogastroenterology. 2003; 50: 843-5.